Chardan Capital Maintains Buy on Intellia Therapeutics, Raises Price Target to $30

Benzinga Newsdesk www.benzinga.com Positive 90.3%

Neg 0% Neu 0% Pos 90.3%

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $27 to $30.